RU2007114112A - Способ получения индазольных соединений - Google Patents

Способ получения индазольных соединений Download PDF

Info

Publication number
RU2007114112A
RU2007114112A RU2007114112/04A RU2007114112A RU2007114112A RU 2007114112 A RU2007114112 A RU 2007114112A RU 2007114112/04 A RU2007114112/04 A RU 2007114112/04A RU 2007114112 A RU2007114112 A RU 2007114112A RU 2007114112 A RU2007114112 A RU 2007114112A
Authority
RU
Russia
Prior art keywords
formula
alkyl
compound
substituted
aryl
Prior art date
Application number
RU2007114112/04A
Other languages
English (en)
Russian (ru)
Inventor
Сринивазан БАБУ (US)
Сринивазан БАБУ
Реймонд Мл. ДАГНИНО (US)
Реймонд Мл. ДАГНИНО
Майкл Аллен УЭЛЛЕТТ (US)
Майкл Аллен УЭЛЛЕТТ
Бинг СИ (US)
Бинг СИ
Куинг-пинг ТИАН (US)
Куинг-пинг ТИАН
Скотт Эдуард ЗУК (US)
Скотт Эдуард ЗУК
Original Assignee
Пфайзер Инк. (US)
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. (US), Пфайзер Инк. filed Critical Пфайзер Инк. (US)
Publication of RU2007114112A publication Critical patent/RU2007114112A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2007114112/04A 2004-11-02 2005-10-21 Способ получения индазольных соединений RU2007114112A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62457504P 2004-11-02 2004-11-02
US60/624,575 2004-11-02
PCT/IB2005/003300 WO2006048745A1 (fr) 2004-11-02 2005-10-21 Methodes de preparation de composes d'indazole

Publications (1)

Publication Number Publication Date
RU2007114112A true RU2007114112A (ru) 2008-12-10

Family

ID=35528034

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007114112/04A RU2007114112A (ru) 2004-11-02 2005-10-21 Способ получения индазольных соединений

Country Status (15)

Country Link
EP (1) EP1809625A1 (fr)
JP (1) JP2008518901A (fr)
KR (1) KR20070058689A (fr)
CN (1) CN101044138A (fr)
AR (1) AR051753A1 (fr)
AU (1) AU2005300311A1 (fr)
BR (1) BRPI0517921A (fr)
CA (1) CA2586176A1 (fr)
IL (1) IL182096A0 (fr)
MX (1) MX2007003603A (fr)
NO (1) NO20072747L (fr)
RU (1) RU2007114112A (fr)
TW (1) TW200614990A (fr)
WO (1) WO2006048745A1 (fr)
ZA (1) ZA200702317B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044045A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
FI2134702T4 (fi) 2007-04-05 2023-09-12 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen
US8354528B2 (en) * 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2163544A1 (fr) * 2008-09-16 2010-03-17 Pfizer, Inc. Méthodes de préparation de composés d' indazole
TW201328725A (zh) 2011-09-30 2013-07-16 Pfizer Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物
MX2014005715A (es) 2011-11-11 2014-05-28 Pfizer N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
CN103387565B (zh) * 2013-07-29 2014-10-29 苏州明锐医药科技有限公司 阿西替尼的制备方法
CN103570696B (zh) * 2013-11-06 2016-02-24 湖南欧亚生物有限公司 一种阿西替尼中间体的制备方法以及在制备阿西替尼中的应用
WO2015067224A1 (fr) 2013-11-08 2015-05-14 Zentiva, K.S. Sels de 6-[2- (méthylcarbamoyl) phénylsulfanyl]-3-e-[2-(pyridin-2-yl) éthanyl]indazole
ES2710211T3 (es) 2014-02-04 2019-04-23 Pfizer Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
ES2647262T3 (es) * 2014-03-31 2017-12-20 Senju Pharmaceutical Co. Ltd Derivado de alquinil indazol y uso del mismo
CN104072484B (zh) * 2014-07-07 2016-07-06 渤海大学 氮-(4-(芳巯基)-1氢-吲唑-3-基)-1-(芳杂环取代)甲基亚胺类化合物及其药学上可接受的盐及其制备方法和应用
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
WO2016057931A1 (fr) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy
RU2714233C2 (ru) 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
CA2989586A1 (fr) 2015-06-16 2016-12-22 Pfizer, Inc. Polytherapies faisant intervenir un antagoniste de pd-l1
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
WO2020128893A1 (fr) 2018-12-21 2020-06-25 Pfizer Inc. Traitements combinés de cancer comprenant un agoniste de tlr
US20220194921A1 (en) 2019-04-18 2022-06-23 Synthon B.V. Process for preparation of axitinib
CN112209861A (zh) * 2019-07-11 2021-01-12 鲁南制药集团股份有限公司 一种阿昔替尼中间体化合物及其制备方法
CN112442010B (zh) * 2019-08-30 2023-10-03 润佳（苏州）医药科技有限公司 一类前药化合物及其在治疗癌症方面的应用
CN111440102B (zh) * 2020-04-26 2022-02-15 大连凯飞化学股份有限公司 一种二硫代二苯甲酰胺类化合物的制备方法
WO2023166420A1 (fr) 2022-03-03 2023-09-07 Pfizer Inc. Anticorps multispécifiques et leurs utilisations
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CN1747950A (zh) * 2002-12-19 2006-03-15 美国辉瑞有限公司 用于治疗眼病的作为蛋白激酶抑制剂的2－(1h－吲唑－6－基氨基)－苯甲酰胺化合物
EP1606283B1 (fr) * 2003-03-03 2008-10-08 Array Biopharma, Inc. Inhibiteurs de la p 38 et leurs procedes d'utilisation
WO2005094823A1 (fr) * 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. INHIBITEUR DE Flt-3

Also Published As

Publication number Publication date
AU2005300311A1 (en) 2006-05-11
CA2586176A1 (fr) 2006-05-11
NO20072747L (no) 2007-07-31
EP1809625A1 (fr) 2007-07-25
JP2008518901A (ja) 2008-06-05
KR20070058689A (ko) 2007-06-08
MX2007003603A (es) 2007-05-21
IL182096A0 (en) 2007-07-24
BRPI0517921A (pt) 2008-10-21
AR051753A1 (es) 2007-02-07
TW200614990A (en) 2006-05-16
ZA200702317B (en) 2008-09-25
WO2006048745A1 (fr) 2006-05-11
CN101044138A (zh) 2007-09-26

Similar Documents

Publication Publication Date Title
RU2007114112A (ru) Способ получения индазольных соединений
RU2009105669A (ru) Способ получения 3-замещенных 2-амино-5-галогенбензамидов
CN102702178B (zh) 拉帕替尼及其盐的制备方法
JP2014532054A5 (fr)
RU2013107023A (ru) Способ получения производных аминобензоилбензофурана
JP2008518900A5 (fr)
JP2020517677A5 (fr)
RU2005125724A (ru) Способ получения фармацевтических средств и соединения, полученные данным способом
CA2515715C (fr) Procedes de production de derives de benzamidine cyclique
HU193258B (en) Process for preparing piperazine derivatives and acid addition salts thereof
JP7200399B2 (ja) アキシチニブの製造方法、中間体２－（（３－ヨード－１ｈ－インダゾール－６－イル）チオ）－ｎ－メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態
JP2023502123A (ja) Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法
ES2360608T3 (es) Bencimidazoles sustituidos y procedimientos de preparación.
KR20020061636A (ko) 항-비만 및 항-당뇨 특성을 갖는 아릴에탄올아민 유도체의제조 방법
GB2073736A (en) Process for Preparing Pyridinyloxyphenoxy Compounds and Derivatives Thereof
RU2007120635A (ru) Способы получения индазольных соединений
KR100373957B1 (ko) 신규한아민유도체,그의제조방법및항부정맥제로서의용도
RU2008134509A (ru) Новые соединения и их применение
RU2021121378A (ru) СИНТЕЗ 3-МЕТИЛ-1,2,4-ТИАДИАЗОЛ-5-КАРБОГИДРАЗИДА ИЛИ ЕГО МЕТИЛ-d3 ДЕЙТЕРИРОВАННОЙ ФОРМЫ
CN111943853B (zh) 一种培唑帕尼杂质的制备方法
CA2882138A1 (fr) Procede de synthese de lactames gamma substitues
KR20220074091A (ko) 아크릴아미드 화합물 및 이의 유도체의 제조방법
CN109438375B (zh) 一种4,5-二苯基取代的三唑类化合物的制备方法
AU2011325809B2 (en) Benzamide derivative with anticancer activity and preparation method and use thereof
CN106749323B (zh) 一种碘佛醇杂质的制备方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090220

FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090220